Want to see NZ:RUA full AI Analyst Report?
Rua Bioscience Ltd. (RUA) AI Stock Analysis
Rua Bioscience Ltd.
(NZX:RUA)
The score is primarily held down by weak financial performance, driven by persistent large losses and ongoing cash burn despite improving revenue. Technicals also add pressure, with the price below key moving averages and negative MACD indicating a weak trend. Valuation contributes only modestly because the negative P/E reflects losses and there is no dividend yield support.
Rua Bioscience Ltd. (RUA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 6.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 91.16K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 1.10
- Revenue Growth
- 70.82%
- EPS Growth
- 41.04%
- Country
- NZ
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Rua Bioscience Ltd. Business Overview & Revenue Model
Company Description
Rua Bioscience Limited, a company founded in 2016 and headquartered in Gisborne, New Zealand, is dedicated to the investigation, refinement, and production of medicinal products for both the New Zealand market and international distribution. Their of...
Rua Bioscience Ltd. Financial Statement Overview
Summary
Revenue is growing (about +21% in 2025 and +10% in 2026), but profitability remains extremely weak with large, persistent net losses and deeply negative net margins. Cash flow is also consistently negative with ongoing operating and free cash flow burn. The balance sheet is relatively steadier with positive equity and only moderate leverage, though debt has risen and ROE is sharply negative.
Income Statement
18Very NegativeBalance Sheet
52NeutralCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.58M | 2.58M | 1.90M | 85.84K | 357.68K | 24.23K |
| Gross Profit | -2.52M | -1.26M | 923.23K | -118.31K | 18.12K | -5.22M |
| EBITDA | -3.44M | -2.96M | -2.86M | -13.30M | -5.25M | -6.63M |
| Net Income | -3.36M | -3.36M | -3.46M | -13.72M | -5.96M | -8.64M |
Balance Sheet | ||||||
| Total Assets | 7.17M | 7.17M | 6.77M | 7.74M | 20.95M | 33.57M |
| Cash, Cash Equivalents and Short-Term Investments | 533.70K | 533.70K | 241.42K | 895.13K | 4.56M | 9.94M |
| Total Debt | 1.76M | 1.76M | 735.60K | 147.78K | 114.58K | 824.00K |
| Total Liabilities | 2.92M | 2.92M | 1.88M | 973.13K | 830.31K | 9.38M |
| Stockholders Equity | 4.25M | 4.25M | 4.89M | 6.77M | 20.12M | 24.20M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -3.02M | -2.72M | -3.60M | -5.80M | -7.18M |
| Operating Cash Flow | -3.02M | -3.02M | -2.72M | -3.60M | -5.73M | -6.78M |
| Investing Cash Flow | -302 | -302 | 105.76K | 2.21M | 6.67M | 5.59M |
| Financing Cash Flow | 3.31M | 3.31M | 1.95M | -94.78K | -120.38K | -208.64K |
Rua Bioscience Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:RUA, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 51.12 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:RUA.
Rua Bioscience Ltd. Peers Comparison
Overall Rating
NZ:TAH70Outperform
NZ:PHL63Neutral
NZ:BLT60Neutral
NZ:AFT54Neutral- NZ:RUA44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NZ:TAH | 70Outperform | NZD 41.81M | 15.00 | ― | 3.83% | 21.56% | 18.96% |
| NZ:PHL | 63Neutral | NZD 36.33M | 0.03 | ― | ― | 29.55% | -11.97% |
| NZ:BLT | 60Neutral | NZD 29.42M | 46.00 | ― | ― | 16.01% | -28.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| NZ:AFT | 54Neutral | NZD 487.67M | 32.88 | 14.07% | 0.63% | 22.44% | 23.14% |
| NZ:RUA | 44Neutral | NZD 11.77M | -2.60 | ― | ― | 70.82% | 41.04% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:RUA | Rua Bioscience Ltd. | 0.03 | -0.00 | -10.34% | |
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.65 | 1.62 | 53.67% | |
| NZ:BLT | BLIS Technologies Limited | 0.02 | 0.01 | 43.75% | |
| NZ:PHL | Promisia Healthcare Limited | 0.67 | 0.18 | 35.35% | |
| NZ:TAH | Third Age Health Services Limited | 4.20 | -0.45 | -9.70% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026